Atlas Trials

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Clinical trial NCT03330847 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03330847
Sponsor
AstraZeneca
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Triple Negative Breast Cancer
Start date
2018-03-07
Primary completion
2020-11-13
Enrollment
273

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.